Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Chapin S. Korosec, Suzan Farhang‐Sardroodi, David W. Dick, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Monkeypox: a review of epidemiological modelling studies and how modelling has led to mechanistic insight
Marina Banuet-Martínez, Yang Yang, Behnaz Jafari, et al.
Epidemiology and Infection (2023) Vol. 151
Open Access | Times Cited: 15
Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV
Vitaliy Matveev, Erik Z. Mihelic, Erika Benko, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107915-107915
Open Access | Times Cited: 15
Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design
Bruna Clemente, Maxime Denis, Camila P. Silveira, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series
Chapin S. Korosec, David W. Dick, Iain R. Moyles, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines
Grace L. Williamson, Eric M. Bachelder, Kristy M. Ainslie
Molecular Pharmaceutics (2024) Vol. 21, Iss. 3, pp. 1015-1026
Closed Access | Times Cited: 5
Mechanistic models of humoral kinetics following COVID-19 vaccination
Daniel Stocks, Amy Thomas, Adam Finn, et al.
Journal of The Royal Society Interface (2025) Vol. 22, Iss. 222
Open Access
Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics
Jiawei Zhou, Rohit Rao, Mark Shapiro, et al.
Clinical Pharmacology & Therapeutics (2025)
Open Access
A mathematical model of protein subunits COVID-19 vaccines
Samaneh Gholami, Chapin S. Korosec, Suzan Farhang‐Sardroodi, et al.
Mathematical Biosciences (2023) Vol. 358, pp. 108970-108970
Open Access | Times Cited: 10
Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: Parameter estimates, identifiability, sensitivity and the eclipse phase profile
Chapin S. Korosec, Matthew Betti, David W. Dick, et al.
Journal of Theoretical Biology (2023) Vol. 564, pp. 111449-111449
Open Access | Times Cited: 10
Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans
Iain R. Moyles, Chapin S. Korosec, Jane M. Heffernan
Journal of Mathematical Biology (2023) Vol. 86, Iss. 5
Open Access | Times Cited: 10
Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine
Dylan A. Hendy, Yutian Ma, Timothy A. Dixon, et al.
Journal of Controlled Release (2024) Vol. 372, pp. 168-175
Closed Access | Times Cited: 3
Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2
Quentin Clairon, Mélanie Prague, Delphine Planas, et al.
PLoS Computational Biology (2023) Vol. 19, Iss. 8, pp. e1011282-e1011282
Open Access | Times Cited: 9
Antibody response elicited by the SARS‐CoV‐2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Irene Schiavetti, Matilde Inglese, Jessica Frau, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 8, pp. 2357-2364
Open Access | Times Cited: 8
A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protection
Prashant Dogra, Carmine Schiavone, Zhihui Wang, et al.
JCI Insight (2023) Vol. 8, Iss. 13
Open Access | Times Cited: 8
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults
Satoshi Iwata, Andrew J. Pollard, Yukio Tada, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Association between vaccination status and severe health consequences among community-dwelling COVID-19 patients during Omicron BA.1/BA.2 and BA.5-predominant periods in Japan
Kimiko Tomioka, Kenji Uno, Masahiro Yamada
Environmental Health and Preventive Medicine (2023) Vol. 28, pp. 35-35
Open Access | Times Cited: 7
Within-host evolution of SARS-CoV-2: how often are de novo mutations transmitted from symptomatic infections?
Chapin S. Korosec, Lindi M. Wahl, Jane M. Heffernan
Virus Evolution (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
The RNA ligation method using modified splint DNAs significantly improves the efficiency of circular RNA synthesis
Yoon‐Seob Kim, Do‐Hyung Kim, Daegi An, et al.
Animal Cells and Systems (2023) Vol. 27, Iss. 1, pp. 208-218
Open Access | Times Cited: 6
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial
Mathieu Le Gars, Jerald Sadoff, Vicky Cárdenas, et al.
Vaccine (2024) Vol. 42, Iss. 19, pp. 3938-3952
Open Access | Times Cited: 1
Vaccine‐induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?
Julien Favresse, Marie Tré‐Hardy, Constant Gillot, et al.
Heliyon (2024) Vol. 10, Iss. 16, pp. e36116-e36116
Open Access | Times Cited: 1
Minimal determinants for lifelong antiviral antibody responses in BALB/c mice from a single exposure to virus-like immunogens at low doses
Wei-Yun Wholey, Alexander R. Meyer, Sekou-Tidiane Yoda, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans
Anna Dari, Philippe Jacqmin, Yuki Iwaki, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 10, pp. 1485-1498
Open Access | Times Cited: 3
Predictors of SARS-CoV-2 IgG Spike Antibody Responses on Admission and Clinical Outcomes of COVID-19 Disease in Fully Vaccinated Inpatients: The CoVax Study
Eleni Livanou, Erasmia Rouka, Sotirios I. Sinis, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 4, pp. 640-640
Open Access | Times Cited: 5
Monkeypox: A review of epidemiological modelling studies and how modelling has led to mechanistic insight
Chapin S. Korosec, Marina Banuet-Martínez, Yang Yang, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV
Vitaliy Matveev, Erik Z. Mihelic, Erika Benko, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top